Abstract :

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. This paper aim was to provide an overview of recent advancements in the treatment of IBS, focusing on the management of its main symptoms: diarrhea, constipation, and abdominal pain.

For individuals with IBS-D, various therapeutic options are available, including rifaximin, peripheral opioid agonists, mixed opioid agonists/antagonists, bile acid sequestrants, and serotonin 5-HT3 receptor antagonists. Rifaximin, a nonabsorbable antibiotic, has demonstrated significant effectiveness in reducing IBS symptoms, such as bloating and loose stools, with good tolerability and safety. Also the repeated use of rifaximin for managing recurrent IBS symptoms. In IBS-C patients, bulking agents, osmotic laxatives, and prokinetic agents like lubiprostone have shown efficacy in improving constipation and overall symptoms. Linaclotide, a drug that increases intestinal chloride secretion, has demonstrated significant improvement in bowel movements and abdominal pain in IBS-C patients. However, it may cause diarrhea in some individuals. IBS-M, characterized by alternating constipation and diarrhea, poses a challenge in terms of specific drug treatments. A comprehensive assessment of potential underlying causes and careful history taking is crucial for effective management. Abdominal pain is a common symptom in IBS, regardless of subtype. Antispasmodic drugs, peppermint oil, and trimebutine have shown effectiveness in reducing pain and improving symptoms. Antidepressants, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may offer relief by modulating pain pathways and influencing gastrointestinal motility. Benzodiazepines, particularly dextofisopam, have shown potential in improving stool consistency but require further evaluation.

In conclusion, recent advancements in the treatment of IBS have provided a range of therapeutic options targeting its main symptoms. However, further research is needed to develop tailored treatments for specific IBS subtypes and to explore the efficacy of potential alternatives, including benzodiazepines. Improved management of IBS symptoms can significantly enhance the quality of life for affected individuals.

---

Keywords :

Constipation, Diarrhea, Irritable bowel syndrome, Treatment.

---

References :

1. Adriani, A., Ribaldone, D. G., Astegiano, M., Durazzo, M., Saracco, G. M., & Pellicano, R. (2018). Irritable bowel syndrome: the clinical approach. Panminerva Medica, 60(4), 213-222.
2. Bonetto, S., Fagoonee, S., Battaglia, E., Grassini, M., Saracco, G. M., & Pellicano, R. (2021). Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med, 131(7-8), 709-715. doi:10.20452/pamw.16067
3. Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008). A placebo-controlled trial of prucalopride for severe chronic constipation. New england journal of medicine, 358(22), 2344-2354.
4. Chapman, R., Stanghellini, V., Geraint, M., & Halphen, M. (2013). Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Official journal of the American College of Gastroenterology| ACG, 108(9), 1508-1515.
5. Chey, W. D., Kurlander, J., & Eswaran, S. (2015). Irritable bowel syndrome: a clinical review. Jama, 313(9), 949-958.
6. Delvaux, M., & Wingate, D. (1997). Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. Journal of international medical research, 25(5), 225-246.
7. Drossman, D., Chey, W. D., Johanson, J., Fass, R., Scott, C., Panas, R., & Ueno, R. (2009). Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome–results of two randomized, placebo‐controlled studies. Alimentary pharmacology & therapeutics, 29(3), 329-341.
8. Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Functional gastrointestinal disorders 2 irritable bowel syndrome. Lancet, 396(10263), 1675-1688.
9. Frissora, C. L., & Schiller, L. R. (2023). Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let’s Make a Diagnosis. Current Gastroenterology Reports, 1-10.
10. Gorard, D., Libby, G., & Farthing, M. (1995). Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Digestive diseases and sciences, 40, 86-95.
11. Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., . . . Forbes, W. P. (2016). Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology, 151(6), 1113-1121.
12. Leventer, S., Raudibaugh, K., Frissora, C., Kassem, N., Keogh, J., Phillips, J., & Mangel, A. (2008). Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome. Alimentary pharmacology & therapeutics, 27(2), 197-206.
13. Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006). Functional bowel disorders. Gastroenterology, 130(5), 1480-1491.
14. Longstreth, G. F., Wilson, A., Knight, K., Wong, J., Chiou, C.-F., Barghout, V., . . . Ofman, J. J. (2003). Irritable bowel syndrome, health care use, and costs: a US managed care perspective. The American journal of gastroenterology, 98(3), 600-607.
15. Lovell, R. M., & Ford, A. C. (2012). Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical gastroenterology and hepatology, 10(7), 712-721. e714.
16. Martínez-Vázquez, M., Vázquez-Elizondo, G., González-González, J., Gutiérrez-Udave, R., Maldonado-Garza, H., & Bosques-Padilla, F. (2012). Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Revista de Gastroenterologia de Mexico, 77(2), 82-90.
17. Nelson, A. D., Black, C. J., Houghton, L. A., Lugo‐Fagundo, N. S., Lacy, B. E., & Ford, A. C. (2021). Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Alimentary pharmacology & therapeutics, 54(2), 98-108.
18. Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., . . . Forbes, W. P. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. New england journal of medicine, 364(1), 22-32.
19. Rao, S., Lembo, A. J., Shiff, S. J., Lavins, B. J., Currie, M. G., Jia, X. D., . . . Eng, P. (2012). A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. The American journal of gastroenterology, 107(11), 1714.
20. Saha, L. (2014). Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of Gastroenterology: WJG, 20(22), 6759.
21. Salari, P., & Abdollahi, M. (2011). Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World Journal of Gastroenterology: WJG, 17(38), 4251.
22. Tack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J., Lacy, B., . . . De Maeyer, J. (2012). Systematic review: cardiovascular safety profile of 5‐HT 4 agonists developed for gastrointestinal disorders. Alimentary pharmacology & therapeutics, 35(7), 745-767.